Weekly Recap: Interim Phase 2/3 QRX003 success and Lake Street $20.00 target
Quoin Pharmaceuticals. Ltd Sponsored ADR (NASDAQ:QNRX) reported positive interim Phase 2/3 QRX003 results for Netherton syndrome and launched a private placement of up to $50M to potentially fund operations through H2 2029, while Lake Street set a $20.00 price target.Previous Week RecapThis is an A…